Kintor is producing a cosmetic with KX826, starting at 0.5% concentration and moving to 1%. The 0.5% concentration wasn't as effective as minoxidil and finasteride, but the 1% concentration shows promise.
The conversation is about the potential of SCUBE3 to regrow a juvenile hairline. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
The conversation is about a person's hair improvement after 14.5 months using RU58841 and Minoxidil topically at 50 mg each day, with noticeable hairline improvement but incomplete crown area recovery. The person struggles to take good pictures of their crown area.
The conversation discusses hair regrowth treatments, including stem cell exosomes, PRP, and PP405. Users question the effectiveness of the treatments and mention finasteride and minoxidil.
The user experienced significant hair improvement over two years using finasteride, minoxidil foam, and ketoconazole, despite some initial shedding and a side effect of watery semen. They are satisfied with the results and encourage others to persist with their treatment.
Treatments for hair loss, with the user considering Pyrilutamide and RU58841 as options. It is noted that although Pyrilutamide has been studied more and is allegedly more effective, there are doubts about its authenticity in the market. KX-826 is suggested as an alternative as it has a stronger effect than RU58841 and there is scientific research on it.
Microneedling can still be beneficial when using oral finasteride and minoxidil, with a recommended needle length of 0.5mm to 1.0mm. A stamp or pen is preferred over a roller for microneedling.
A user warns against buying the Koreabeautics V2 microneedling pen, claiming it's marketed through fake success stories and is overpriced. Another user shares their experience, acknowledging the pen's quality but agreeing it's too expensive and reliant on frequent needle head replacements.
A user is concerned about the impact of topical dutasteride on sperm quality and potential long-term fertility issues. They are using microneedling with a 0.025% dutasteride solution and are seeking information on whether sperm parameters return to normal after stopping the drug.
Kintor KX-826, a hair loss treatment, is being discussed for its pricing and effectiveness, with a focus on whether the 0.9% concentration is more effective than the 0.5%. Users are seeking cheaper purchasing options.
Microneedling promotes hair growth by increasing circulation and collagen production, with gains potentially lasting longer than those from minoxidil. Some users report sustained results after stopping microneedling, unlike with minoxidil and finasteride.
The user started taking 1 mg finasteride daily in September 2024 and began derma stamping twice a week, noticing progress initially but now experiencing increased scalp visibility. They are considering adding oral or topical minoxidil to their routine for further improvement.
The conversation is about the long-term use of RU58841 for hair loss, with users sharing their experiences and seeking information on its effectiveness and whether it needs to be used continuously like minoxidil or finasteride.
A user shared their six-month hair regrowth journey using Kirkland minoxidil, micro-needling, keto shampoo, and hims topical spray with minoxidil and finasteride. They reported noticeable hair improvement with minimal side effects and plan to continue the routine.
The user experienced increased hair shedding after one month on 0.25 mg finasteride, despite initial improvement. This shedding may be a normal phase in the hair cycle and could improve in the coming months.
The user experienced increased hair shedding after adding tretinoin to their regimen of finasteride, minoxidil, and dermarolling, but noticed new vellus hairs appearing. They plan to restart tretinoin more gently, as some users suggest shedding indicates treatment effectiveness, while others warn it may cause severe thinning for a minority.
Microneedling combined with tretinoin is discussed for its effectiveness in treating hair loss. Minoxidil, finasteride, and RU58841 are also mentioned as potential treatments.
User shares 8-month progress on oral finasteride and minoxidil, noting initial success followed by a second shed. They seek advice on drug resistance and pill efficacy, with responses suggesting to push through the shed and consider the impact of cycling off minoxidil.
The conversation is about the effectiveness of Redensyl for hair loss and whether to continue using Minoxidil alone, despite planning for a hair transplant eventually. The user also mentions using dermarolling, PRP therapy, and Nutrafol.
Hair/scalp cloning for unlimited transplants is likely a decade away, with prior transplants not significantly affecting future options. Advances in AI and research in wound-induced hair neogenesis are promising, but infrastructure and technology constraints remain challenges.
A user is using Minoxidil, finasteride, saw palmetto, and Minimalist RCP serum to address hair thinning, with some success but concerns about the long-term benefits of Minimalist. They plan to continue Minoxidil and finasteride for another year before considering a hair transplant.
The user experienced severe hair loss after using minoxidil and finasteride, then switched to dutasteride and RU58841 with some success. They are considering trying minoxidil again, possibly with topical tretinoin, despite concerns about shedding.
KX-826 Max combines KX-826, Kopyrrol, and Kopexil as a potential alternative to minoxidil and finasteride for hair loss, but users express skepticism about its effectiveness and high cost. Some users believe traditional treatments like minoxidil, finasteride, and others are more reliable.
A 25-year-old male experienced hair loss after taking breaks from oral dutasteride and minoxidil, leading to concerns about losing progress. He is advised to remain consistent with his current regimen and avoid adding spironolactone.
Redensyl improved hair thickness slightly with no side effects, but no regrowth. Minoxidil provided significant regrowth but caused facial side effects like puffiness.
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.